IGI Logo

Zydus Lifesciences is currently trading at Rs. 355.70, up by 11.85 points or 3.45% from its previous closing of Rs. 343.85 on the BSE.

The scrip opened at Rs. 350.75 and has touched a high and low of Rs. 360.50 and Rs. 348.00 respectively. So far 40236 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 331.00 on 07-Mar-2022.

Last one week high and low of the scrip stood at Rs. 360.50 and Rs. 331.00 respectively. The current market cap of the company is Rs. 35201.39 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.66% and 9.46% respectively.

Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences, and BridgeBio Pharma, Inc. (BridgeBio), have executed an asset purchase agreement (the Agreement) for the sale of BridgeBio’s NULIBRY (Fosdenopterin) for injection. NULIBRY is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder.

With the asset purchase of NULIBRY, Zydus Lifesciences aims at bridging unmet healthcare needs of children with rare and orphan paediatric diseases. The company’s wholly owned subsidiary Sentynl is also facilitating early diagnosis and treatment by enhancing awareness, new-born screening, genetic testing and patient support across multiple products and rare diseases including the development of a treatment for Menkes Disease, currently under rolling review by the USFDA, for which it partnered with Cyprium Therapeutics, Inc. (Cyprium).

Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.